Peter Wehling
Overview
Explore the profile of Peter Wehling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
235
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buchheit T, Huh Y, Breglio A, Bang S, Xu J, Matsuoka Y, et al.
Brain Behav Immun
. 2023 May;
111:298-311.
PMID: 37150265
Chemotherapy-induced peripheral neuropathy (CIPN) is the most prevalent neurological complication of chemotherapy for cancer, and has limited effective treatment options. Autologous conditioned serum (ACS) is an effective biologic therapy used...
2.
Wehling P, Evans C, Wehling J, Maixner W
Ther Adv Musculoskelet Dis
. 2017 Aug;
9(8):183-196.
PMID: 28835778
Osteoarthritis is a painful, chronic disease with widespread burden on patients, communities, health and social care systems. Conservative therapies, such as nonpharmacological interventions, systemic drug treatment and intra-articular therapies are...
3.
Evans C, Chevalier X, Wehling P
Phys Med Rehabil Clin N Am
. 2016 Oct;
27(4):893-908.
PMID: 27788906
Autologous conditioned serum was developed in the mid 1990s as an expeditious, practical, and relatively inexpensive means of generating the interleukin-1 receptor antagonist, a naturally occurring inhibitor of the cytokine...
4.
Wehling P, Moser C, Maixner W
Ther Adv Musculoskelet Dis
. 2016 Jun;
8(3):72-85.
PMID: 27247634
The objectives of osteoarthritis (OA) management are to reduce pain and inflammation, slow cartilage degradation, improve function and reduce disability. Current strategies for managing knee OA include nonpharmacological interventions, oral...
5.
Fischer K, Dieterich R, Nelson M, Kamphuis L, Singh K, Rotter B, et al.
Theor Appl Genet
. 2015 Jul;
128(10):2121-30.
PMID: 26169875
A novel and highly effective source of anthracnose resistance in narrow-leafed lupin was identified. Resistance was shown to be governed by a single dominant locus. Molecular markers have been developed,...
6.
Wehling P
Poiesis Prax
. 2012 Dec;
9(1-2):43-60.
PMID: 23204995
In recent years, citizens' and civil society engagement with science and technology has become almost synonymous with participation in institutionally organized formats of participatory technology assessment (pTA) such as consensus...
7.
Wehling P, Viehover W, Gundel H
Dtsch Arztebl Int
. 2012 Jun;
109(18):339-40.
PMID: 22679457
No abstract available.
8.
Wehling P
Poiesis Prax
. 2011 Dec;
8(2-3):67-82.
PMID: 22207827
The fact that the emergence of "technoscience," resulting from the coalescing of science and technology, may have serious social and cultural impact has been debated in recent years particularly with...
9.
Scholz M, Ruge-Wehling B, Habekuss A, Schrader O, Pendinen G, Fischer K, et al.
Theor Appl Genet
. 2009 Jul;
119(5):837-49.
PMID: 19585100
Barley yellow dwarf virus (BYDV) causes high yield losses in most of the major cereal crops worldwide. A source of very effective resistance was detected within the tetraploid wild species...
10.
Wehling P, Reinecke J, Baltzer A, Granrath M, Schulitz K, Schultz C, et al.
Hum Gene Ther
. 2008 Nov;
20(2):97-101.
PMID: 18986219
This paper provides the first evidence of a clinical response to gene therapy in human arthritis. Two subjects with rheumatoid arthritis received ex vivo, intraarticular delivery of human interleukin-1 receptor...